BioSpace News Archive

Saama Technologies, Inc., the #1 AI clinical analytics platform company, and iNDX.Ai, a leading Multi-omics Data Analytics and translational research platform company, announced the launch of the new COVID-19 Command Center.

A new fund raising round for Defymed, to allow the entry into clinical phase of its ExOlin® device

The first U.S. patients have been dosed in a clinical trial testing whether four experimental mRNA vaccine candidates can prevent infection with the virus that causes COVID-19 disease..

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization, has been selected to commercially manufacture the treatment Clevegen for partner Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company.

CollPlant, a regenerative and aesthetics medicine company, announced that it will be hosting a webinar on Tuesday, May 12, 2020 at 11 am EDT/6 pm IDT that will feature its Co-Founder and Chief Scientist, Professor Oded Shoseyov and Chief Executive Officer, Mr. Yehiel Tal.

NuVasive, Inc. announced the expansion of its Advanced Materials Science™ implant portfolio with the commercial launch of the Modulus® XLIF® Dual Sided Plate, and the receipt of 510 clearances from the U.S. Food and Drug Administration for Modulus ALIF and Cohere® TLIF-O.

Baxter International Inc. announced an increase in the company’s quarterly cash dividend to a rate of $0.245 per share of common stock.

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema, announces a $66 million financing led by Ally Bridge Group, a leading global life science investor. The financing also attracted new investors Adage Capital Management, HealthQuest Capital, Partner Fund Management, and Rock Springs Capital, as well as existing investors. I

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), today announced an interview with its CEO, Dr. Faz Chowdhury, will be available for viewing beginning Monday, May 11, 2020, on RedChip Companies

CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced it will expand its testing efforts for the novel coronavirus, or COVID-19. The Company was previously testing in Germany’s Mecklenburg-Western Pomerania region, and will now be offeri